ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. The company's Monocyte Targeting Technology (MTT) is designed to selectively block the migration of monocytes from the blood stream into inflamed tissues. With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, The company is advancing its solution (IW-601) to a Ph1 clinical trial.
Cumulative Funding Raised Over Time ($)
Employees Over Time
ImmuneWalk Therapeutics Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jun 11, 2025
www.biospace.com
ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601
#Product Stage
May 7, 2025
www.globenewswire.com
ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences
ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601
#Product Stage
May 7, 2025
www.globenewswire.com
ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences